Literature DB >> 15574769

Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.

Sandra L Krueckl1, Robert A Sikes, N Magnus Edlund, Robert H Bell, Antonio Hurtado-Coll, Ladan Fazli, Martin E Gleave, Michael E Cox.   

Abstract

Apoptosis and inhibition of mitosis are primary mechanisms mediating androgen ablation therapy-induced regression of prostate cancer (PCa). However, PCa readily becomes androgen independent, leading to fatal disease. Up-regulated growth and survival signaling is implicated in development of resistance to androgen ablation therapy. We are testing the hypothesis that insulin-like growth factor (IGF) responsiveness is required for androgen-independent (AI) progression. Using the LNCaP human PCa progression model, we have determined that IGF-I-mediated protection from apoptotic stress and enhanced mitotic activity is androgen dependent in LNCaP cells but is androgen independent in lineage-derived C4-2 cells. Both cell lines exhibit androgen-responsive patterns of IGF-I receptor (IGF-IR) expression, activation, and signaling to insulin receptor substrate-2 and AKT. However, C4-2 cells express higher levels of IGF-IR mRNA and protein and exhibit enhanced IGF-I-mediated phosphorylation and downstream signaling under androgen-deprived conditions. In comparisons of naive and AI metastatic human PCa specimens, we have confirmed that IGF-IR levels are elevated in advanced disease. Together with our LNCaP/C4-2 AI progression model data, these results indicate that increased IGF-IR expression is associated with AI antiapoptotic and promitotic IGF signaling in PCa disease progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15574769     DOI: 10.1158/0008-5472.CAN-04-2446

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Authors:  Gary E Gallick; Paul G Corn; Amado J Zurita; Sue-Hwa Lin
Journal:  Future Med Chem       Date:  2012-01       Impact factor: 3.808

2.  Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.

Authors:  Ashish B Rajput; Melinda A Miller; Alessandro De Luca; Niki Boyd; Sam Leung; Antonio Hurtado-Coll; Ladan Fazli; Edward C Jones; Jodie B Palmer; Martin E Gleave; Michael E Cox; David G Huntsman
Journal:  J Clin Pathol       Date:  2007-01-26       Impact factor: 3.411

3.  Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells.

Authors:  Li-Hua Chen; Jing Fang; Zhijian Sun; Huaixing Li; Ying Wu; Wendy Demark-Wahnefried; Xu Lin
Journal:  J Nutr       Date:  2009-02-11       Impact factor: 4.798

Review 4.  Growth factor and signaling pathways and their relevance to prostate cancer therapeutics.

Authors:  Jocelyn L Wozney; Emmanuel S Antonarakis
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

5.  Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling.

Authors:  Mohammad Saleem; Imtiyaz Murtaza; Rohinton S Tarapore; Yewseok Suh; Vaqar Mustafa Adhami; Jeremy James Johnson; Imtiaz Ahmad Siddiqui; Naghma Khan; Mohammad Asim; Bilal Bin Hafeez; Mohammed Talha Shekhani; Benyi Li; Hasan Mukhtar
Journal:  Carcinogenesis       Date:  2009-02-20       Impact factor: 4.944

6.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

7.  Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence.

Authors:  Xi Zheng; Xiao-Xing Cui; Zhi Gao; Yang Zhao; Yong Lin; Weichung Joe Shih; Mou-Tuan Huang; Yue Liu; Arnold Rabson; Bandaru Reddy; Chung S Yang; Allan H Conney
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

8.  Ligand-independent activation of MET through IGF-1/IGF-1R signaling.

Authors:  Andreas Varkaris; Sanchaika Gaur; Nila U Parikh; Jian H Song; Farshid Dayyani; Jung-Kang Jin; Christopher J Logothetis; Gary E Gallick
Journal:  Int J Cancer       Date:  2013-04-17       Impact factor: 7.396

9.  A comprehensive in silico analysis of the functional and structural impact of SNPs in the IGF1R gene.

Authors:  S A de Alencar; Julio C D Lopes
Journal:  J Biomed Biotechnol       Date:  2010-06-23

10.  "Topological significance" analysis of gene expression and proteomic profiles from prostate cancer cells reveals key mechanisms of androgen response.

Authors:  Adaikkalam Vellaichamy; Zoltán Dezso; Lellean JeBailey; Arul M Chinnaiyan; Arun Sreekumar; Alexey I Nesvizhskii; Gilbert S Omenn; Andrej Bugrim
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.